Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanxun Yang

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
International Journal of Clinical and Experimental Pathology|December 1, 2015
Programmed cell death 2 functions as a tumor suppressor in osteosarcomaYuanxun Yang, Yan Jin, Wenxi Du
Clinical Pharmacology in Drug Development|July 20, 2023
Pharmacokinetic and Bioequivalence Evaluation of Single-Tablet and Separate-Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy SubjectsLei Huang, Jing Lei, Yuanxun Yang, et al.
Molecular Biomedicine|May 7, 2026
The m<sup>6</sup>A reader IGF2BP2 promotes hepatocellular carcinoma progression via enhancing RELB stabilityHehua Ma, Yuxin Hong, Zhi Xu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 11, 2025
Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokineticsKeli Wang, Juefang Ding, Minlu Cheng, et al.
Frontiers in Endocrinology|February 12, 2025
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitusHaoyi Yang, Yuwen Zhang, Yuxin Hong, et al.
Diabetes, Obesity & Metabolism|June 5, 2025
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 studyQinghua Wang, Qiaoli Cui, Yulong Xu, et al.
Cell Death Discovery|January 15, 2022
ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulationWei Song, Fei Fei, Fengchang Qiao, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 19, 2023
A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitusLei Huang, Bei Cao, Yan Geng, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 9, 2023
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjectsBei Cao, Lei Huang, Ming Liu, et al.
Investigational New Drugs|April 11, 2024
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjectsBei Cao, Tingting Ma, Yuqiang Zhang, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
International Journal of Clinical and Experimental Pathology|December 1, 2015
Programmed cell death 2 functions as a tumor suppressor in osteosarcomaYuanxun Yang, Yan Jin, Wenxi Du
Clinical Pharmacology in Drug Development|July 20, 2023
Pharmacokinetic and Bioequivalence Evaluation of Single-Tablet and Separate-Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy SubjectsLei Huang, Jing Lei, Yuanxun Yang, et al.
Molecular Biomedicine|May 7, 2026
The m<sup>6</sup>A reader IGF2BP2 promotes hepatocellular carcinoma progression via enhancing RELB stabilityHehua Ma, Yuxin Hong, Zhi Xu, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 11, 2025
Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): Effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokineticsKeli Wang, Juefang Ding, Minlu Cheng, et al.
Frontiers in Endocrinology|February 12, 2025
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitusHaoyi Yang, Yuwen Zhang, Yuxin Hong, et al.
Diabetes, Obesity & Metabolism|June 5, 2025
Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 studyQinghua Wang, Qiaoli Cui, Yulong Xu, et al.
Cell Death Discovery|January 15, 2022
ALKBH5-mediated N<sup>6</sup>-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulationWei Song, Fei Fei, Fengchang Qiao, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 19, 2023
A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitusLei Huang, Bei Cao, Yan Geng, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 9, 2023
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjectsBei Cao, Lei Huang, Ming Liu, et al.
Investigational New Drugs|April 11, 2024
The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjectsBei Cao, Tingting Ma, Yuqiang Zhang, et al.
Pageof 2